Better Options for Lymphatic Filariasis Treatment

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

5,100

Participants

Timeline

Start Date

March 31, 2026

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2028

Conditions
Lymphatic FilariasisScabiesStrongyloidiasis
Interventions
DRUG

MoxDA - Moxidectin + Diethylcarbamzine (DEC) + Albendazole

"Mass drug administration with moxidectin co-administered with DEC and albendazole (MoxDA).~Participants who are ineligible to receive moxidectin will be offered modified treatment options:~1. Children aged ≥ 2 years but \< 4 years - DEC, albendazole, and permethrin 5% cream~2. Participants who have a severe illness, a known or suspected allergy to ivermectin, moxidectin, DEC or albendazole, are pregnant or breastfeeding a baby up to 7 days of age, or are under 2 years of age - permethrin 5% cream (unless allergic)"

DRUG

IDA - Ivermectin + DEC + albendazole

"Mass drug administration with ivermectin co-administered with DEC and albendazole (IDA).~Participants who are ineligible to receive moxidectin will be offered modified treatment options:~1. Children aged \< 2 years or weight \< 15 kg - DEC, albendazole, and permethrin 5% cream~2. Participants who have a severe illness, a known or suspected allergy to ivermectin, moxidectin, DEC or albendazole, are pregnant or breastfeeding a baby up to 7 days of age, or are under 2 years of age - permethrin 5% cream (unless allergic)"

Trial Locations (1)

Unknown

Ministry of Health and Medical Services Fiji, Suva

All Listed Sponsors
collaborator

Murdoch Childrens Research Institute

OTHER

collaborator

Kirby Institute

OTHER_GOV

lead

Medicines Development for Global Health

OTHER